News

Public · Published

Guggenheim maintains Neurocrine Biosciences at Buy, raises price target to $224 from $207

Guggenheim kept its Buy rating on Neurocrine Biosciences and raised its price target to $224 from $207. The new target is 8.2% higher and implies 35.9% upside from the November 3 closing price of $164.85. Five recent analyst targets ranged from $185 to $220.

Published:

Updated:

What happened

Guggenheim kept its Buy rating on Neurocrine Biosciences and raised its price target to $224 from $207. The new target is 8.2% higher and implies 35.9% upside from the November 3 closing price of $164.85. Five recent analyst targets ranged from $185 to $220.

Confirmed

Global impact / market context

The higher target signals that Guggenheim sees more potential value in Neurocrine shares, which could influence investor expectations and trading decisions. However, a price target is an analyst estimate, not a promised outcome, and other recent analysts set targets both below and near Guggenheim’s new figure.

Analyst inference

Recent analyst opinions on Neurocrine Biosciences varied, with reported price targets ranging from $185 to $220 and ratings including Equal-Weight, Outperform, Buy, and Overweight. Guggenheim’s $224 target exceeds that range, which may shape investor expectations but does not establish future performance.

Analyst inference

What to watch

  1. Compare future analyst targets and ratings with Guggenheim’s $224 estimate to see whether other firms also raise their expectations or retain lower valuations. Analyst inference
  2. Check subsequent company updates for evidence that could affect revenue, costs, or expected earnings; the supplied article gives no business results or reasons for Guggenheim’s change. Analyst inference
  3. The reported target implies 35.9% upside from the November 3 close of $164.85, but it remains an analyst estimate rather than a guaranteed share-price outcome. Confirmed

Evidence

  • Original source link unavailable